159 related articles for article (PubMed ID: 14530481)
1. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
Buchegger F; Bonvin F; Kosinski M; Schaffland AO; Prior J; Reubi JC; Bläuenstein P; Tourwé D; García Garayoa E; Bischof Delaloye A
J Nucl Med; 2003 Oct; 44(10):1649-54. PubMed ID: 14530481
[TBL] [Abstract][Full Text] [Related]
2. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
3. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
Gabriel M; Decristoforo C; Wöll E; Eisterer W; Nock B; Maina T; Moncayo R; Virgolini I
Cancer Biother Radiopharm; 2011 Oct; 26(5):557-63. PubMed ID: 21883013
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of a new, stabilized neurotensin(8--13) pseudopeptide radiolabeled with (99m)tc.
García-Garayoa E; Bläuenstein P; Bruehlmeier M; Blanc A; Iterbeke K; Conrath P; Tourwé D; Schubiger PA
J Nucl Med; 2002 Mar; 43(3):374-83. PubMed ID: 11884498
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
7. Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc.
Nock BA; Nikolopoulou A; Reubi JC; Maes V; Conrath P; Tourwé D; Maina T
J Med Chem; 2006 Jul; 49(15):4767-76. PubMed ID: 16854083
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the Profile of [
Kanellopoulos P; Nock BA; Krenning EP; Maina T
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114537
[TBL] [Abstract][Full Text] [Related]
9. New neurotensin analogue radiolabeled by 99m-technetium as a potential agent for tumor identification.
Emrarian I; Sadeghzadeh N; Abedi SM; Abediankenari S
Chem Biol Drug Des; 2018 Jan; 91(1):304-313. PubMed ID: 28816013
[TBL] [Abstract][Full Text] [Related]
10. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
11. The role of technetium-99m-labeled octreotide acetate scintigraphy in suspected breast cancer and correlates with expression of SSTR.
Wang F; Wang Z; Wu J; Qu W; Yao W; Zhao J; Liu Z
Nucl Med Biol; 2008 Aug; 35(6):665-71. PubMed ID: 18678351
[TBL] [Abstract][Full Text] [Related]
12. Double-stabilized neurotensin analogues as potential radiopharmaceuticals for NTR-positive tumors.
García-Garayoa E; Maes V; Bläuenstein P; Blanc A; Hohn A; Tourwé D; Schubiger PA
Nucl Med Biol; 2006 May; 33(4):495-503. PubMed ID: 16720241
[TBL] [Abstract][Full Text] [Related]
13. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
14. Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors.
Alshoukr F; Rosant C; Maes V; Abdelhak J; Raguin O; Burg S; Sarda L; Barbet J; Tourwé D; Pelaprat D; Gruaz-Guyon A
Bioconjug Chem; 2009 Aug; 20(8):1602-10. PubMed ID: 19610615
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans.
Kemerink GJ; Boersma HH; Thimister PW; Hofstra L; Liem IH; Pakbiers MT; Janssen D; Reutelingsperger CP; Heidendal GA
Eur J Nucl Med; 2001 Sep; 28(9):1373-8. PubMed ID: 11585297
[TBL] [Abstract][Full Text] [Related]
16. Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Janssen PJ; de Visser M; Verwijnen SM; Bernard BF; Srinivasan A; Erion JL; Breeman WA; Vulto AG; Krenning EP; de Jong M
Cancer Biother Radiopharm; 2007 Jun; 22(3):374-81. PubMed ID: 17651043
[TBL] [Abstract][Full Text] [Related]
17. Radionuclide imaging of small-cell lung cancer (SCLC) using 99mTc-labeled neurotensin peptide 8-13.
Zhang K; An R; Gao Z; Zhang Y; Aruva MR
Nucl Med Biol; 2006 May; 33(4):505-12. PubMed ID: 16720242
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection.
Rennen HJ; Boerman OC; Oyen WJ; Corstens FH
J Nucl Med; 2003 Sep; 44(9):1502-9. PubMed ID: 12960199
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study.
Decristoforo C; Maina T; Nock B; Gabriel M; Cordopatis P; Moncayo R
Eur J Nucl Med Mol Imaging; 2003 Sep; 30(9):1211-9. PubMed ID: 12845487
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of
Prignon A; Provost C; Alshoukr F; Wendum D; Couvelard A; Barbet J; Forgez P; Talbot JN; Gruaz-Guyon A
Mol Pharm; 2019 Jun; 16(6):2776-2784. PubMed ID: 31013092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]